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Abstract
Even though cell death modalities elicited by anticancer chemotherapy and radiotherapy have been extensively
studied, the ability of anticancer treatments to induce non-cell-autonomous death has never been investigated. By
means of multispectral imaging ﬂow-cytometry-based technology, we analyzed the lethal fate of cancer cells that
were treated with conventional anticancer agents and co-cultured with untreated cells, observing that anticancer
agents can simultaneously trigger cell-autonomous and non-cell-autonomous death in treated and untreated cells.
After ionizing radiation, oxaliplatin, or cisplatin treatment, fractions of treated cancer cell populations were eliminated
through cell-autonomous death mechanisms, while other fractions of the treated cancer cells engulfed and killed
neighboring cells through non-cell-autonomous processes, including cellular cannibalism. Under conditions of
treatment with paclitaxel, non-cell-autonomous and cell-autonomous death were both detected in the treated cell
population, while untreated neighboring cells exhibited features of apoptotic demise. The transcriptional activity of
p53 tumor-suppressor protein contributed to the execution of cell-autonomous death, yet failed to affect the non-cellautonomous death by cannibalism for the majority of tested anticancer agents, indicating that the induction of noncell-autonomous death can occur under conditions in which cell-autonomous death was impaired. Altogether, these
results reveal that chemotherapy and radiotherapy can induce both non-cell-autonomous and cell-autonomous death
of cancer cells, highlighting the heterogeneity of cell death responses to anticancer treatments and the unsuspected
potential contribution of non-cell-autonomous death to the global effects of anticancer treatment.

Introduction
From the initial discovery of programmed cell death
during animal development1 to the recent identiﬁcation of
entotic death during embryo implantation2, a cornucopia
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of cell death modalities has been identiﬁed and shown to
play a role in numerous physiological or pathological
situations3, 4. Mainly studied as clonal cellular responses
to lethal stress, cell death processes have been deﬁned on
the basis of their speciﬁc morphological features (e.g.,
apoptotic, autophagic, or necrotic), their metabolic and
biochemical characteristics (e.g., the loss of mitochondrial
transmembrane potential, the exposure of phosphatidylserine (PS) on the outer leaﬂet side, or the rupture of
plasma membrane integrity), their enzymatic and
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catabolic activities (involving (or not) caspases, receptorinteracting protein kinases (RIPKs), mixed lineage kinase
domain-like proteins, or cathepsins), and in relation to
their ability to elicit an inﬂammatory reaction or to stimulate an immune response. A classiﬁcation of cell death
modalities built on these criteria has been proposed5 and
led to the ordering of lethal processes into three distinct
types: type I cell death (or apoptosis), type II cell death (or
autophagic cell death), and type III cell death (or necrosis). All these processes, which are executed in a cellautonomous manner, can be induced in the targeted
stressed cells or at a distance, in the neighboring cells
(through bystander effects). These processes are known as
cell-autonomous death (CAD)6. Despite major progresses
that have been made in the ﬁeld, the relative contribution
of both direct and bystander-signal-mediated killing
triggered by typical CAD remains poorly explored.
Cell death subroutines (such as mitotic death and corniﬁcation) that do not or partially exhibit the typical
morphological and biochemical hallmarks of cell death
have been less studied and are listed in a poorly deﬁned
subgroup of cell death modalities known as atypical cell
death5. In recent years, additional cell death mechanisms
(such as entosis or emperitosis) have been described and
associated with this neglected subgroup of cell death
modalities7, 8. Their examination revealed the existence of
cell death processes that are elicited after the engulfment
of live cells by neighboring live cells. These lethal processes are also known as non-cell-autonomous death
(NCAD). The ﬁrst step of NCAD programs, which start
with the interaction of two cellular partners through
membrane adhesion receptors (such as E- or P-cadherins)
or stress receptors (such as lipoprotein receptor-related
protein), requires the formation of adherent junctions
between interacting cells and the activation of signaling
pathways, which may involve small GTPases (such as
Rho9 and cell division cycle 42 (CDC42)10) and ROCK
kinases7, on both interacting cells. The modulation of
actomyosin contractility and the reorganization of the
actin cytoskeleton in “target” cells also favor their invasion
into host cells9, 11. This process is distinct from cellular
cannibalism, which can also trigger NCAD through the
activation of speciﬁc signaling pathways (such as
phagocytosis-related signaling pathways that involve
CDC42, chemokine (C-X-C motif) ligand 1 (CXCL1) or
CXCL6) on host cells and leads to the active engulfment
of target cells10. Independently of the precise cell
engulfment process, engulfed cells are targeted by “host”
lysosomal enzymes (such as cathepsins and granzymes)
and eliminated through distinct lethal mechanisms that
may involve major modulators of typical cell death (such
as cytochrome c, caspases, or autophagy-related (ATG)
proteins). When NCAD leads to the apoptotic demise of
engulfed cells, the process is called phagoptosis12–14 or
Ofﬁcial journal of the Cell Death Differentiation Association
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emperipolesis15. This form of cell death has been proposed to occur frequently in the body12 and to control
erythrocyte, neutrophil, platelet, and T cell homeostasis12,
16, 17
. The engulfment of natural killer cells by tumor cells
was also shown to induce emperitosis, which is a programmed cell-in-cell death process that requires caspase3 activation and leads to DNA fragmentation8. Inversely,
entosis, another form of NCAD initially described after
homotypic interactions between breast cancer cells, is a
cell-in-cell invasion mechanism that does not require the
activation of caspases to eliminate engulfed cells7. We
recently deﬁned NCAD as type IV cell death6.
Despite intensive biological and pharmaceutical
research programs that have helped to better characterize
cellular and biochemical processes associated with anticancer treatment, the ability of anticancer agents to
simultaneously induce CAD and NCAD has never been
investigated. Here, using novel multispectral imaging
ﬂow-cytometry-based methodology, we show that cancer
cells respond to treatment with various anticancer agents
by undergoing simultaneously several death modalities
that can be either cell-autonomous or non-cellautonomous and are distinctly impacted by the tumorsuppressive factor p53, revealing unsuspected heterogeneity of cell death responses to anticancer treatment.

Results
Ionizing radiation (IR) induces CAD of irradiated cancer
cells

Even though radiotherapy is one of the most frequent
anticancer treatments used in the clinic, the lethal
mechanisms responsible for the therapeutic effects of
radiotherapy are still largely unknown. Lethal processes
(such as apoptosis and mitotic catastrophe) that have
been detected in response to IR were never directly
implicated in treatment efﬁciency18, suggesting that
additional, uncharacterized cell death modalities may
contribute to the therapeutic effects of radiotherapy. To
precisely analyze the cellular mechanisms through which
cancer cells may simultaneously undergo direct and
bystander cell killing in response to IR, we designed a
novel cell death proﬁling assay based on co-culture of
untreated cancer cells that have been labeled with the red
ﬂuorescent probe 5-(and-6)-(((4-chloromethyl)benzoyl)
amino) tetramethylrhodamine (CMTMR) and irradiated
isogenic cancer cells that have been labeled with the green
ﬂuorescent probe 5-chloromethylﬂuorescein diacetate
(CMFDA). After different times of co-culture and exposure to different doses of IR, irradiated CMFDA+ cells,
non-irradiated CMTMR+ cells, and the total cell population (CMFDA+ and CMTMR+) were analyzed for PS
exposure, loss of plasma membrane integrity, and DNA
content (Fig. 1a). The simultaneous detection of the
above-indicated parameters allowed us to detect, through
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Fig. 1 Detection of cell-autonomous and non-cell-autonomous death by confocal microscopy and quantitative imaging ﬂow cytometry. a
Principle of cell death proﬁling by quantitative ﬂow imaging. Before co-culture, treated and non-treated cancer cells were, respectively, labeled with
CMFDA (green) or CMTMR (red) ﬂuorescent vital probes. After 24 h of co-culture, cancer cells were analyzed for non-cell-autonomous death (NCAD)
(by detecting the engulfment of CMTMR- or CMFDA-labeled cancer cells), the phosphatidylserine (PS) exposure (using Biotin-AnnexinV and BV786Streptavidin), the loss of plasma integrity (by following with DRAQ7 uptake), and the DNA content (using Hoechst 33342). Using quantitative ﬂow
cytometry, the simultaneous detection of NCA death (also known as type IV cell death) and of typical cell death (type I, II, and III) in both non-treated
and treated cancer cell populations, the cell death proﬁling is determined for various anticancer treatments. b Validation of multiparametric and
simultaneous detection of cell death modalities by quantitative imaging ﬂow cytometry induced by γ-irradiation on human colon carcinoma HCT116
cells. Representative images are shown (scale, 20 μm)

the use of multispectral imaging ﬂow cytometry, the
execution of at least four types of cell death (including
several lethal pathways, such as apoptosis, mitotic death,
pyroptosis, autophagic cell death, necrosis, necroptosis,
entosis, emperitosis, and cellular cannibalism) on target
cells and on neighboring cells (Fig. 1b), thus discriminating CAD from NCAD and direct cell killing from
bystander lethal effects.
Thus CMFDA-labeled HCT116 human colon cancer
cells (wild-type (WT) HCT116 (HCT116WT) cells, isogenic control HCT116 (HCT116+/+) cells, and
HCT116p53R248W/+ cells harboring the dominant-negative
mutant of p53, p53R248W (Fig. 2a–h), or MCF7 human
breast cancer cells (Fig. 2i–n) were irradiated with different doses (0, 4, 8, and 16 Gy), mixed after 24 h with
Ofﬁcial journal of the Cell Death Differentiation Association

CMTMR-labeled isogenic cells (1:1 ratio), and cultured
for the indicated times. PS exposure, plasma membrane
integrity, and DNA content of each population were then
determined by means of AnnexinV-BV786 (AV), DRAQ7
(D7), and Hoechst 33342 staining, respectively. Although
no signiﬁcant increase of apoptotic and necrotic cell death
was observed in the untreated control cell population (as
revealed by the detection of AnnexinV+DRAQ7−
(AV+D7−), AnnexinV−DRAQ7+ (AV−D7+), and
AnnexinV+DRAQ7+ (AV+D7+) cells (Fig. 2a, c–h)), a
signiﬁcant increase of AV+D7− cells and AV+D7+ cells
was detected in the total population of HCT116WT or
HCT116+/+ cells (as revealed by CMFDA+ and
CMTMR+ cells) (Fig. 2b, c, f, o), in neighboring
HCT116WT or HCT116+/+ cells (CMTMR+ cells)
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Fig. 2 (See legend on next page.)

(Fig. 2b, d, g, p), and in irradiated HCT116WT or
HCT116+/+ cells (CMFDA+ cells) (Fig. 2b, e, h, q). These
processes were observed in a dose-dependent manner
after 24 h (Fig. 2c–e) and 48 h (Fig. 2f–h) of co-culture,
demonstrating that our methodology allows us to score
the death of both non-irradiated and irradiated cells.
These results were conﬁrmed after 12 h (Fig. 2i–k) and 24
h (Fig. 2l–n) of co-culture of control or irradiated
CMFDA-labeled MCF7 cells with untreated CMTMROfﬁcial journal of the Cell Death Differentiation Association

labeled MCF7 cells. To characterize molecular mechanisms involved in the execution of these cell death processes, co-cultures of HCT116WT cells were performed in
the presence of cell death modulators (Supplementary
Figures 1a-e). Thus the ROCK-1 inhibitor Y27632 was
used as an inhibitor of live cell engulfment following
procedures of previously published reports7. The peptide
derivatives benzyloxycarbonyl-Val-Ala-Asp(OMe)-ﬂuoromethylketone (Z-VAD-fmk) and YVAD-cmk were used
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(see ﬁgure on previous page)
Fig. 2 Detection of γ-irradiation–elicited CAD modalities by quantitative imaging ﬂow cytometry. a–h Detection and quantiﬁcation of plasma
membrane integrity loss (with DRAQ7) and PS exposure (with BV786-streptavidin/Annexin V biotin) were achieved for total cell populations
(CMTMR+ or CMFDA+ HCT116WT cells (a, o), HCT116+/+ cells (c, f), and MCF7 cells (i, l)), for the untreated (red) CMTMR+ cell populations (HCT116WT
cells (a, b, o–q), HCT116+/+ cells (c, d, f, g), and MCF7 cells (i, j, l, m)), for untreated (green) CMFDA+ cell populations (HCT116WT cells (a, o, q),
HCT116+/+ cells (c, e, f, h), and MCF7 cells (i, k, l, n)), and for treated (green) CMFDA+ cell populations (HCT116WT cells (b, o, q), HCT116+/+ cells (c, e,
f, h), and MCF7 cells (i, k, l, n). CAD modalities were detected after 12-h (i–k), 24-h (a–e), or 48-h (f–h) co-culture of untreated (red) CMTMR-labeled
cells with untreated (green) CMFDA-labeled cells (a, c, f, i, l) or of untreated (red) CMTMR-labeled cells with (green) CMFDA-labeled cells that have
been irradiated with the indicated doses of γ-ionizing radiation (b, d, e, g, j, k, m, n). o–q Co-cultures of HCT116WT cells were also performed during
24 h in the presence or absence of the indicated pharmacological death effector inhibitors. CAD modalities were determined as previously described
for the untreated (red) CMTMR+ HCT116WT cells, for untreated (green) CMFDA+ HCT116WT cells, for treated (green) CMFDA+ HCT116WT cells, and for
total cell population (CMTMR+ or CMFDA+ HCT116WT cells). Representative dot plots (a, b) and quantitative data (c–q) are shown (means ± SEM, n = 3).
For c–h, asterisk (*) is used for the comparison of “HCT116+/++Irr. HCT116+/+” with “HCT116+/++0 Gy HCT116+/+” for AV+D7− and ampersand (&)
is used for the comparison of “HCT116+/++Irr. HCT116+/+” with “HCT116+/++0 Gy HCT116+/+” for D7+. For i–n, asterisk (*) is used for the
comparison of “MCF7+Irr. MCF7” with “MCF7+0 Gy MCF7” for AV+D7− and ampersand (&) for the comparison of “MCF7+Irr. MCF7” with “MCF7+0
Gy MCF7” for D7+. For o–q, asterisk (*) is used for comparison of “HCT116WT+4 Gy control (Co.) HCT116WT” with “HCT116WT+control (Co.) HCT116WT”
for AV+D7−, hash (#) for the comparison of inhibitor-treated cells with respective control cells for AV+D7− and dollar symbol ($) for the comparison
of inhibitor-treated cells with respective control cells for D7+. *, #, &p < 0.05; **, ##, &&p < 0.01; ***, ###, $$$, &&&p < 0.001; and ****, ####, $$$$, &&&&p < 0.0001

as pan-caspase or caspase-1 inhibitors, respectively19, 20,
and the RIPK1 inhibitor necrostatin-1 (NEC1) was
employed as necroptosis inhibitor21. Baﬁlomycin A1
(BafA1) and the cyclin-dependent kinase inhibitor roscovitine (Rosco) were used to analyze the contribution of
autophagic ﬂux and mitotic progression, respectively22–24.
We observed that the pan-caspase inhibitor Z-VAD-fmk
reduced the exposure of PS on the plasma membrane of
the total cell population of HCT116WT cells (Fig. 2o), of
irradiated CMFDA+ HCT116WT cells (Fig. 2q), and to a
lower extent, those of non-irradiated CMTMR+
HCT116WT cells (Fig. 2p). These results conﬁrm the
notion that irradiated CMFDA+ cells die efﬁciently in the
event of caspase activation25. However, co-culture
experiments performed with MCF7 cells that are deﬁcient for caspase-3 revealed that both total (Fig. 2i, l) and
irradiated cell population (Fig. 2j, n) also exhibited a signiﬁcant increase of AV+D7− and AV+D7+ cells (as
compared to control cells), thus indicating that irradiated
cancer cells can also die through caspase-3-independent
death. In addition, the impairment of autophagic ﬂux with
BafA1 increased the frequency of dying cells (AV+D7−,
AV+D7−, and AV+D7+ cells) in the total cell population
(CMFDA+ and CMTMR+ cells) (Fig. 2o), in nonirradiated CMTMR+ cells (Fig. 2p), and in irradiated
CMFDA+ cells (Fig. 2q), pointing to autophagy as a prosurvival mechanism that contributes to rescue both nonirradiated and irradiated cells from death. The simultaneous analysis of the progression of non-irradiated and
irradiated HCT116WT cells (Supplementary Figures 2a,
2b, and 2o-2s), HCT116+/+ cells (Supplementary Figures 2c-2h), or MCF7 cells (Supplementary Figures 2i-2n)
through their cell cycle compartment distribution showed
that cell death induction was associated with the accumulation of irradiated cell populations in G2/M and 4N
phases (Supplementary Figures 2a-2q). No alteration of
Ofﬁcial journal of the Cell Death Differentiation Association

the cell cycle was detected in the non-irradiated
CMTMR+ cell populations (Supplementary Figures 2b,
2d, 2g, 2j, 2m, and 2p), implying that the cell cycle
alterations were only detected in irradiated cells (Supplementary Figures 2b, 2e, 2h, 2k, 2n, and 2q). These
results were conﬁrmed by classical ﬂow-cytometric analysis (Supplementary Figures 2r and 2s). Altogether, these
results demonstrate that IR eliminates cancer cells mainly
through direct cell killing.
Paclitaxel induces CAD of both treated and neighboring
cells

To further evaluate whether chemotherapeutic agents
may also eliminate cancer cells by eliciting distinct cell
death modalities, we examined the cell death features
triggered by paclitaxel (PCT) (a taxane currently used in
breast cancer treatment) and by oxaliplatin (OXA) and
cisplatin (CDDP), two platinum salts that are frequently
used to treat colorectal and non-small cell lung cancers,
respectively. Thus CMFDA-labeled HCT116+/+ cells
(Fig. 3a–f), HCT116WT (Fig. 3m–o), or MCF7 cells
(Fig. 3g–l) were treated with the indicated concentrations
of PCT (Fig. 3), OXA, or CDDP (Fig. 4) during 24 h, then
mixed at a 1:1 ratio with CMTMR-labeled cells, and
cultured for 12, 24, or 48 h in the absence or presence of
cell death inhibitors. Multispectral imaging ﬂowcytometric analysis revealed that, after the treatment
with PCT, both untreated CMTMR+ cells (Fig. 3b, e, h, k)
and PCT-treated CMFDA+ cells (Fig. 3c, f, i, l) were
eliminated in a dose-dependent manner, by apoptosis (as
compared to control cells (Fig. 3a–l)). Accordingly, the
pan-caspase inhibitor Z-VAD-fmk inhibited the exposure
of PS on the outer plasma membrane leaﬂet of both
untreated CMTMR+ cells and PCT-treated CMFDA+
cells (Fig. 3m–o). Co-cultures of untreated CMTMRlabeled MCF7 cells with CMFDA-labeled MCF7 cells that
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Fig. 3 (See legend on next page.)
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(see ﬁgure on previous page)
Fig. 3 Quantitative imaging ﬂow-cytometric detection of CAD modalities induced by paclitaxel. The cell death proﬁling was performed after
co-cultures of untreated (red) CMTMR-labeled HCT116WT, HCT116+/+, or MCF7 cells with untreated (green) CMFDA-labeled cells or with paclitaxel
(PCT)-treated (green) CMFDA-labeled HCT116WT, HCT116+/+, or MCF7 cells. Co-cultures have been performed during 12 h (g–i), 24 h (a–c, j–o) or 48
h (d–f) with the indicated concentrations of PCT in the presence or absence of death effector inhibitors. Then cells were sequentially labeled for the
simultaneous detection of type I, II, or III cell death as previously described. Means ± SEM are indicated (n = 3). For a–f, asterisk (*) is used for the
comparison of “HCT116+/++PCT-treated HCT116+/+” with “HCT116+/++0 nM HCT116+/+” for AV+D7−, ampersand (&) is used for the comparison of
“HCT116+/++PCT-treated HCT116+/+” with “HCT116+/++0 nM HCT116+/+” for D7+. For g–l, asterisk (*) is used for the comparison of “MCF7+PCTtreated MCF7” cells with “MCF7+0 nM MCF7” for AV+D7−, and ampersand (&) is used for the comparison of “MCF7+PCT-treated MCF7” with “MCF7
+0 nM MCF7” for D7+. For m–o, asterisk (*) is used for the comparison of “HCT116WT+PCT-treated control (Co.) HCT116WT” with “HCT116WT+control
(Co.) HCT116WT” for AV+D7−, ampersand (&) for the comparison of “HCT116WT+PCT-treated control (Co.) HCT116WT” cells with “HCT116WT+control
(Co.) HCT116WT” cells for D7+, hash (#) for the comparison of inhibitor-treated cells with respective control cells for AV+D7−, and dollar symbol ($) for
the comparison of inhibitor-treated cells with respective control cells for D7+. *, #, &p < 0.05; **, ##, $$, &&p < 0.01; ***, ###, &&&p < 0.001; and ****, &&&&p <
0.0001

had been treated with PCT during 24 h revealed after 12 h
(Fig. 3g–i) or 24 h (Fig. 3j–l) that, in the absence of caspase-3, untreated CMTMR+ cells and PCT-treated
CMFDA+ cells were mainly eliminated through necrosis
(as revealed by the detection of untreated and treated
A−D7+ or A+D7+ MCF7 cells (Fig. 3j–l)). In contrast to
PCT, which induced marked bystander killing (Fig. 3),
OXA and CDDP had a less strong bystander effect (Fig. 4).
Thus the fraction of OXA- or CDDP-treated CMFDA+
cells that underwent apoptosis was larger than that of
untreated CMTMR+ cells (Fig. 4a–c, j–l). These processes, which were inhibited by the pan-caspase inhibitor
Z-VAD-fmk, indicate that a fraction of single HCT116WT
cells underwent apoptosis after treatment with OXA or
CDDP (Fig. 4j–l). In the absence of caspase-3 (in MFC7
cells), these treatments also killed cancer cells to a lower
extent, mainly through a necrotic process (Fig. 4d–i). We
observed that PCT-, OXA-, and CDDP-treated
HCT116WT and HCT116+/+ cells and neighboring cells
of PCT-treated cells accumulated in the G2/M phase of
the cell cycle (Supplementary Figures 3 and 4). Moreover,
OXA- and CDDP-treated MCF7 cells accumulated in the
S phase (Supplementary Figure 4). In addition, pharmacological inhibition of caspases (with Z-VAD-fmk) and of
Cdk1 (with Rosco) failed to interfere with this G2/M
arrest (Supplementary Figures 3m-3o and 4m-4o), indicating that killing of both treated and neighboring cells
was not associated with cell cycle progression. These
results demonstrate that chemotherapeutic agents such as
PCT can exert their cytotoxic effects on cancer cells
through direct and indirect cell-autonomous lethal
pathways.
IR, PCT, OXA, and CDDP also induce NCAD

In parallel, we examined in the same co-cultures the
ability of irradiated or PCT-, OXA-, or CDDP-treated
CMFDA+ cells to engulf or invade neighboring cells, two
cellular processes required for induction of cellular
cannibalism-associated cell death (e.g., as cellular cannibalism or phagoptosis) or cell-in-cell invasion-elicited cell
Ofﬁcial journal of the Cell Death Differentiation Association

death (e.g., as entosis or emperitosis). Multispectral imaging ﬂow-cytometric analysis revealed that irradiated or
treated CMFDA+ HCT116WT, HCT116+/+, or MCF7
cells triggered the engulfment of neighboring cells after
12, 24, and 48 h of co-culture (as revealed by the internalization of “target” CMTMR+ (red) cells by IR-, PCT-,
OXA-, or CDDP-treated CMFDA+ (green) cells detected
with multispectral imaging ﬂow cytometry (Figs. 5a–e, j–l
and 6) and confocal microscopy (Fig. 5f–h)). This process
was repressed by the inhibitor of ROCK1 (Y27632) but
was not affected by the pan-caspase inhibitor Z-VAD-fmk
(ZVAD) (Fig. 5d, h and 6f, l), indicating that the detected
cell-in-cell internalization is distinct from phagocytic
uptake of apoptotic cells and requires ROCK1 activity.
Importantly, the cell death proﬁling analysis allowed us to
distinguish between live cell engulfment and phagocytosis
of apoptotic CMFDA+ cells by live CMTMR+ cells that
follows apoptosis induced by treatment with BafA1
(Figs. 5d and 6f) or with high concentrations (100 μM and
1 mM) of OXA or CDDP (Fig. 6h–l). We then evaluated
the fate of engulfed CMTMR+ HCT116WT cells and those
of irradiated or PCT-, OXA-, or CDDP-treated engulﬁng
CMFDA+ HCT116WT cells. We observed that approximately 50% of engulfed CMTMR+ HCT116WT cells
exhibited signs of cellular degradation, as revealed by a
decreased size of internalized cells detected with multispectral imaging ﬂow cytometry (Figs. 5a, e and 6a, g, m)
and the DNA content loss of internalized cells detected by
confocal microscopy (Fig. 5f, g, i). This process was partially reduced in the presence of the pan-caspase inhibitor
Z-VAD-fmk, demonstrating that the death of engulfed
cells occurs through caspase-dependent and caspaseindependent mechanisms (Figs. 5i and 6g). To explore the
lethal mechanisms through which engulfed cells are
eliminated, we detected and quantiﬁed by ﬂuorescent
microscopy the release of cytochrome c, caspase-3 cleavage, and nuclear fragmentation in engulfed cells obtained
after homotypic cultures of HCT116WT cells. Within
cannibal cells elicited by IR, PCT, OXA, or CDDP treatment, the engulfed cells exhibited signs of apoptosis such
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Fig. 4 Quantitative imaging ﬂow-cytometric detection of CAD modalities induced by oxaliplatin or cisplatin. The cell death proﬁling was
performed after co-cultures of untreated (red) CMTMR-labeled HCT116WT, HCT116+/+, or MCF7 cells with untreated (green) CMFDA-labeled cells or
with oxaliplatin (OXA)-treated or cisplatin (CDDP)-treated (green) CMFDA-labeled HCT116WT, HCT116+/+, or MCF7 cells. Co-cultures have been
performed during 12 h (d–f) and 24 h (a–c, g–l) with the indicated concentrations of OXA or CDDP in the presence or absence of death effector
inhibitors. As previously described, cells were labeled for the simultaneous detection of type I, II, or III cell death. Means ± SEM are indicated (n = 3).
For a–c, asterisk (*) is used for the comparison of “HCT116+/++OXA- or CDDP-treated HCT116+/+” with “HCT116+/++0 nM HCT116+/+” for AV+D7−,
hash (&) is used for the comparison of “HCT116+/++OXA- or CDDP-treated HCT116+/+” with “HCT116+/++0 nM HCT116+/+” for D7+. For d–i,
asterisk (*) is used for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0 nM MCF7” cells for AV+D7− and ampersand (&) is used
for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0 nM MCF7” for D7+. For j–l, asterisk (*) is used for comparison of
“HCT116WT+OXA- or CDDP-treated control (Co.) HCT116WT” with “HCT116WT+control (Co.) HCT116WT” for AV+D7−, ampersand (&) for the
comparison of “HCT116WT+OXA- or CDDP-treated control (Co.) HCT116WT” with “HCT116WT+control (Co.) HCT116WT” for D7+, hash (#) for the
comparison of inhibitor-treated cells with respective control cells for AV+D7−, and dollar symbol ($) for the comparison of inhibitor-treated cells with
respective control cells for D7+. *, #, $, &p < 0.05; **, ##, $$, &&p < 0.01; ***, ###, $$$, &&&p < 0.001; and ****, ####, $$$$, &&&&p < 0.0001

as cytochrome c release, activating cleavage of caspase-3
and nuclear degradation (Fig. 7a–e). We also determined
the impact of the pan-caspase inhibitor Z-VAD-fmk and
the caspase-1 inhibitor YVAD-cmk on these apoptotic
features. Fluorescence microscopy revealed that Z-VADfmk (but not YVAD-cmk) impaired release of cytochrome
c and activation of caspase-3 in engulfed cells (Fig. 7c, d)
but only partially inhibited nuclear degradation with such
cells (Fig. 7e). These results conﬁrm those obtained using
multispectral ﬂow imaging and clearly demonstrate that
the death of engulfed cells requires the activation of both
caspase-dependent and -independent mechanisms. In
addition, the vast majority of cannibal cells did not expose
PS and did not exhibit loss of the integrity of their
plasma membrane after anticancer treatments (Supplementary Figures 5a-5d) underscoring the fact that, after
IR-, PCT-, OXA-, or CDDP-mediated cell engulfment, the
internalized cells succumb to death without compromising the viability of the engulﬁng cells. Altogether, these
results show that IR and major chemotherapeutic agents
(such as PCT, OXA, and CDDP) can simultaneously
induce CAD and NCAD in both treated and untreated
cells.
The transcriptional activity of p53 tumor-suppressor
protein distinctly impacts the execution of CAD and NCAD
elicited by anticancer treatment

Considering that p53 inactivation is a major cellular
factor involved in the resistance of tumor cells to anticancer treatments26, we analyzed the impact of inhibition of
p53 transcriptional activity on the induction of CAD and
NCAD. Thus we examined the inﬂuence of a dominantnegative mutation at codon 248 in one allele of p53
(p53R248W) on the execution of CAD and NCAD elicited
by IR, PCT, CDDP, or OXA treatment. In parallel to
previous experiments (Figs. 2c–h, 3a–f, 4a–c, 5b, c, and 6b,
c, h, i), CMFDA-labeled HCT116 p53R248W/+ cells were
irradiated with different doses (Fig. 8a, c, e, g) or treated
with the indicated concentrations of PCT, OXA, or CDDP
Ofﬁcial journal of the Cell Death Differentiation Association

(Fig. 8a–h) for 24 h, then mixed at a 1:1 ratio with
CMTMR-labeled cells, and co-cultured for 24 h (Fig. 8a, c,
e, g) or 48 h (Fig. 8b, d, f, h). As described above, PS
exposure, plasma membrane integrity, and DNA content
of each cellular partner were then analyzed using multispectral imaging ﬂow cytometry. As expected, we observed
a signiﬁcant inhibition of PCT-, CDDP-, and OXA-elicited
apoptosis of irradiated or treated HCT116 p53R248W/+ cells
(Fig. 8a, e). In addition, p53 inactivation impaired PCTinduced apoptosis of untreated HCT116 p53R248W/+cells
(Fig. 8c), as compared to control irradiated or treated
HCT116 +/+cells (Figs. 2c–h, 3a–f, 4a–c, 5b, c, and 6b, c,
h, i). Although, p53 inactivation had no impact on IR-,
PCT-, and CDDP-mediated cellular cannibalism, OXAinduced cellular cannibalism was repressed when transcriptional activity of p53 was inhibited (Fig. 8g, h), as
compared to control irradiated or treated HCT116+/+
cells (Fig. 5d and 6b, c, h, i). p53 transcriptional inactivation similarly impacted the progression through the cell
cycles of IR-, PCT-, OXA-, and CDDP-treated
HCT116 p53R248W/+cells (Supplementary Figure 6), as
compared to control cells (Figs. 2c–h, 3a–f, and 4a–c).
Altogether, these results demonstrated that the transcription factor p53 distinctly modulates the induction of
NCAD and emphasizes the conclusion that the stimulation of cannibalistic activity of p53-mutated cancer cells
by anticancer chemotherapies (such as PCT and CDDP)
or radiotherapy should be considered as a treatment
option.

Discussion

Using a novel quantitative multispectral imaging ﬂowcytometry-based platform and co-culture experiments, we
could provide evidence suggesting that IR and chemotherapeutic agents (such as PCT, OXA, and CDDP)
can simultaneously trigger CAD and NCAD in both
treated and untreated cancer cell populations. Thus, for
the ﬁrst time, we observed that, after IR, a fraction of
irradiated cancer cells is eliminated through CAD, while
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Fig. 5 (See legend on next page.)

another fraction of the irradiated cancer cell population
engulfed and killed neighboring cells via both caspasedependent and -independent death mechanisms. Similarly, OXA and CDDP triggered killing of some treated
cancer cells through cell-autonomous apoptosis and
Ofﬁcial journal of the Cell Death Differentiation Association

cellular cannibalism. Interestingly, PCT not only simultaneously induced CAD and NCAD in distinct fractions of
the treated cell population but also caused the apoptosis
of untreated cells co-cultured with PCT-treated cells.
Consistent with prior reports18, 27, these results reveal the
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Fig. 5 Detection of γ-irradiation–elicited NCAD modalities by quantitative imaging ﬂow cytometry and confocal ﬂuorescence microscopy.
a–l Simultaneously to the detection of CAD mechanisms in Fig. 2, cell-in-cell structures and target cell degradation were determined by quantitative
imaging (a–e and j–l) and confocal ﬂuorescent microscopy (f–i) after 24-h (a, b, d–i, l), 48-h (c), or 12-h (j, k) co-culture of untreated (red) CMTMRlabeled HCT116WT cells (a, d–i), HCT116+/+ cells (b, c), or MCF7 cells (j–l) with, respectively, (green) CMFDA-labeled HCT116WT cells (a, d–i), HCT116+/+
cells (b, c), or MCF7 cells (j–l) that have been irradiated or not with 4 Gy of γ-ionizing radiation. Then (red) CMTMR-labeled HCT116 cells internalizing
(green) CMFDA-labeled HCT116 cells (noted R(G)), and (green) CMFDA-labeled HCT116 cells internalizing (red) CMTMR-labeled HCT116 cells (noted G
(R)) were detected and quantiﬁed. Representative images of quantitative imaging are shown in (a, j) (scale, 20 μm). Representative images (a, f, g, j)
and frequencies of cell-in-cell (CIC) structures (b–d, h, k, l) and target cell degradation (e, i) were obtained and quantiﬁed by quantitative imaging
ﬂow cytometry (a–e and j–l) and confocal microscopy (f–i). White arrows indicate CIC structures and white dotted arrows target cell degradation as
observed by confocal microscopy (f, g) (scale bar = 10 μm). Frequencies of CIC structures showing R(G), and G(R) (h) and target cell degradation (i)
have been determined (means ± SEM, n = 3). For b, c, asterisk (*) is used for the comparison of “HCT116+/++Irr.HCT116+/+” with “HCT116+/++0 Gy
HCT116+/+” for G(R), and ampersand (&) is used for the comparison of “HCT116+/++Irr. HCT116+/+” with “HCT116+/++0 Gy HCT116+/+” cells for R
(G). For d, h, asterisk (*) is used for the comparison of “HCT116WT+4 Gy control (Co.) HCT116WT” with “HCT116WT+control (Co.) HCT116WT” for G(R),
ampersand (&) for comparison of “HCT116WT+4 Gy control (Co.) HCT116WT” cells with “HCT116WT+control (Co.) HCT116WT” for R(G), hash (#) for the
comparison of inhibitor-treated cells with control cells for G(R), and dollar symbol ($) for the comparison of inhibitor-treated cells with respective
control cells for R(G). For e, i, hash (#) is used for the comparison of inhibitor-treated cells with respective control cells for target cell degradation. For
k, l, asterisk (*) is used for the comparison of “MCF7+Irr. MCF7” with “MCF7+0 Gy MCF7” for G(R) and ampersand (&) is used for the comparison of
“MCF7+Irr. MCF7” with “MCF7+0 Gy MCF7” for R(G). *, #, &p < 0.05; **, ##, &&p < 0.01; ***, ###, $$$p < 0.001; and ****, ####, $$$$, &&&&p < 0.0001

individual variability of cell responses to death-inducing
stimuli and the coexistence of many types of cell death
subroutines in the same cell population. Thus the global
effect of cell death inducers appears to be more related to
the sum of multiple lethal processes than the consequence
of the execution of a single-cell death modality. These
processes can not only occur through cell-autonomous or
non-cell-autonomous mechanisms and act directly on
treated cells but also through bystander effect on
untreated neighboring cells. Altogether, these results
demonstrate the existence of the heterogeneity of cell
death responses to anticancer treatments and may thus
help to explain the absence of a link between the induction of CAD (such as apoptosis) and the clonogenic survival of cancer cells observed after IR18. Considering that
IR, PCT, and OXA are well-known immunogenic cell
death inducers28, the relative contribution of each CAD
and NCAD to release danger-associated molecular patterns or other immunostimulatory factors and to favor the
development of tumor-speciﬁc immune responses
remains to be determined.
Intriguingly, we observed that the transcriptional
activity of tumor-suppressor p53 distinctly affects the
execution of both CAD and NCAD. The inactivation of
p53 transcriptional activity impaired OXA-induced cellular cannibalism but failed to alter IR-, PCT-, and CDDPmediated cellular cannibalism. These results support the
interpretation that NCAD can be induced in cancer cells
harboring or not dominant-negative mutants of p53 and
should render these cells more sensitive to anticancer
treatment. These results underscore the importance for
further systematic evaluation of the prevalence of CAD
and NCAD both in physiological or pathological situations. Phagoptosis has been detected during the development of the nematode Caenorhabditis elegans29, 30. In
Ofﬁcial journal of the Cell Death Differentiation Association

mammals, phagoptosis has not only been involved in
cellular and tissue homeostasis (e.g., during brain development)12 but also during the inﬂammation and neurodegeneration13. Recently, the gene Ced-10 has been
shown to contribute to the killing of primordial germ cells
by controlling the cannibalistic activity of endodermal
cells31. Considering the normal embryonic development
and near-normal survival of mice lacking apoptotic
pathway components (such as Apaf−/−, Bax−/−, Bak−/−,
or double knockout mice)32, 33, the relative contribution
of NCAD to embryonic development, cellular homeostasis, and cell loss remains to be explored and the
relationship between the induction of CAD and NCAD
in vivo needs to be investigated. In addition, cell death
proﬁling analysis should facilitate the characterization of
alternative cell death mechanisms (such as keratinocyte
death by corniﬁcation34 or entosis7). More importantly,
the mechanistic elucidation of NCAD should help to
revisit several concepts and signaling models that have
been proposed to explain cell death processes. Particular
attention should be paid to partial biological effects or a
shift from one cell death modality to another cell death
that have been detected when cell death effectors (such as
caspases) are inhibited35–38. The relative contribution of
CAD and NCAD to the shift from apoptosis to necroptosis described when Fas-overexpressing L929 ﬁbrosarcoma cells were stimulated by agonistic anti-Fas
antibody in the presence of the pan-caspase inhibitor ZVAD-fmk could be re-analyzed for evaluation of the cell
death proﬁle using quantitative multispectral imaging
ﬂow cytometry. Our results also suggest that the quantitative and qualitative variations of cell death proﬁles elicited by different types of anticancer treatment should
differentially impact biological and immunological tumor
responses to anticancer treatment. Further molecular
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Fig. 6 Quantitative imaging ﬂow-cytometric detection of NCAD modalities triggered by paclitaxel, oxaliplatin, or cisplatin. Simultaneously
to the detection of CAD in Figs. 3 and 4, NCAD mechanisms were determined with the indicated concentrations of PCT, OXA, and CDDP and in the
presence or absence of the indicated inhibitors after co-cultures of untreated (red) CMTMR-labeled cells (HCT116WT cells (a, f, g, l, m), HCT116+/+ cells
(b, c), or MCF7 cells (d, e)) with untreated (green) CMFDA-labeled isogenic cells and after co-cultures of untreated (red) CMTMR-labeled cells
(HCT116WT cells (a, f, g, l, m), HCT116+/+ cells (b, c), or MCF7 cells (d, e)) with PCT-, OXA-, or CDDP-treated (green) CMFDA-labeled isogenic cells. The
detection of cell-in-cell structures (a–f, h–l) and target cell degradation (g, m) were performed as indicated in the legend of Fig. 5. Frequencies are
shown (means ± SEM, n = 3). For b, c, asterisk (*) is used for the comparison of “HCT116+/++PCT-treated HCT116+/+” with “HCT116+/++0 nM
HCT116+/+” for G(R), ampersand (&) is used for the comparison of “HCT116+/++PCT-treated HCT116+/+” with “HCT116+/++0 nM HCT116+/+” for R
(G). For d, e, asterisk (*) is used for comparison of “MCF7+PCT-treated MCF7” with “MCF7+0 nM MCF7” cells for G(R), ampersand (&) is used for the
comparison of “MCF7+PCT-treated MCF7” with “MCF7+0 nM MCF7” cells for R(G). For f, asterisk (*) is used for the comparison of “HCT116WT+PCTtreated HCT116WT” with “HCT116WT+control (Co.) HCT116WT” for G(R), ampersand (&) for the comparison of “HCT116WT+PCT-treated HCT116WT” with
“HCT116WT+control (Co.) HCT116WT” for R(G), hash (#) for the comparison of inhibitor-treated cells with control cells for G(R), and dollar symbol ($) for
the comparison of inhibitor-treated cells with respective control cells for R(G). For g, m, hash (#) is for the comparison of inhibitor-treated cells with
respective control cells for target cell degradation. For h, i, asterisk (*) is used for the comparison of “HCT116+/++OXA- or CDDP-treated HCT116+/+”
with “HCT116+/++0 nM HCT116+/+” cells for G(R), and ampersand (&) is used for the comparison of “HCT116+/++OXA- or CDDP-treated HCT116+/+”
with “HCT116+/++0 nM HCT116+/+” for R(G). For j, k, asterisk (*) is used for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0
nM MCF7” for G(R) and ampersand (&) is used for the comparison of “MCF7+OXA- or CDDP-treated MCF7” with “MCF7+0 nM MCF7” for R(G). For l,
asterisk (*) for the comparison of “HCT116WT+OXA- or CDDP-treated HCT116WT” cells with “HCT116 WT+control (Co.) HCT116 WT” cells for G(R),
ampersand (&) for the comparison of “HCT116 WT+OXA- or CDDP-treated HCT116WT” with “HCT116 WT+control (Co.) HCT116WT” cells for R(G), hash
(#) for the comparison of inhibitor-treated cells with control cells for G(R) and dollar symbol ($) for comparison of inhibitor-treated cells with
respective control cells for R(G). *, #, $, &p < 0.05; **, ##, $$, &&p < 0.01; *** or &&&p < 0.001; and ****, $$$$, &&&&p < 0.0001

characterization deﬁning the impact of each cell death
modality on the global cancer cell fate in vitro and on
tumor growth in vivo should help to unravel the exact
contribution of CAD and NCAD to anticancer treatment.
Taken together, our results demonstrate the coexistence
of CAD (such as type I, II, and III cell death modalities)
with NCAD (as the proposed type IV cell death modality)6. Future studies aiming at the pharmacological or
genetic manipulation of cell death effectors (such as
proapoptotic BCL-2 family members, BAX and BAK)
should contribute to mitigate the notion of “the point of
no return,” which has been proposed as the central cellular event for cell fate decision, considering lethal signaling pathways as a linear cascade of molecular events
coming into play in a cell-autonomous fashion5. Indeed,
future analyses must contemplate the heterogeneity of
cellular responses to anticancer agents and IR and admit
the possibility that non-cell autonomous and bystander
effects might play a major role in determining the efﬁcacy
of cancer treatments.

Material and methods
Chemicals, cell lines, and culture conditions

Unless otherwise indicated, chemicals and acetyl-TyrVal-Ala-Asp-chloromethylketone (Ac-YVAD-cmk) were
purchased from Sigma-Aldrich. Antibiotics, media, and
supplements for cell culture were obtained from Life
Technologies. Z-VAD-fmk was from Bachem and
recombinant mouse tumor necrosis factor-alpha from
R&D systems. Human colon carcinoma WT HCT116
(HCT116WT)
cells,
isogenic
dominant-negative
p53R248W-expressing HCT116 (HCT116p53R258W/+)
cells, WT p53 control HCT116 (HCT116+/+) cells,
Ofﬁcial journal of the Cell Death Differentiation Association

human MCF7 breast cancer cells, and murine ﬁbrosarcoma cell line L929 were cultured in Dulbecco’s
modiﬁed Eagle’s medium. HCT116p53R258W/+ cells and
HCT116+/+ cells are isogenic pairs of cells obtained from
WT HCT116 (HCT116WT). Jurkat T cells were maintained in RPMI medium. All the media were supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 10 mM HEPES buffers, 2 mM L-glutamine, 10 U/
mL penicillin sodium, and 10 μg/mL streptomycin sulfate.
Irradiation and treatment with chemotherapeutic agents

Cells were seeded in 6-well plates, 12-well plates, or 25
cm2 ﬂasks for 24 h. Then adherent cells were treated with
different concentrations of PCT, OXA, or CDDP or
irradiated at the indicated dose with gamma-ray irradiator
IBL-637 (Cs137, 1 Gy/min, gamma CIS-BioInternational,
IBA, Saclay, France) during 24 h.
CellTracker™ ﬂuorescent probes labeling and co-culture
experiments

Upon the removal of the culture medium, cancer cells
were incubated with prewarmed medium containing 10
μM of CMFDA (green ﬂuorescence) or CMTMR (red
ﬂuorescence) (Molecular Probes-Life Technologies) for
45 min at 37 °C. Thereafter, cancer cells were rinsed twice
with prewarmed medium and incubated for 45 min at 37 °C.
Stained cells were then detached with Tryspin-EDTA
solution (Life Technologies), suspended in complete
medium, and cultured for the indicated times for cell
death proﬁling or confocal microscopic analysis.
Untreated cancer cells were labeled with CMFDA (green
ﬂuorescence, CMFDA+) or CMTMR (red ﬂuorescence,
CMTMR+) and treated cancer cells with CMFDA (green
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Fig. 7 Detection of biochemical features of engulfed cells detected after OXA, CDDP-PCT or IR treatment. a, b Representative ﬂuorescent
images of cytochrome c release, cleavage of CASP3, and nuclear degradation in engulfed HCT116WT cells detected after 24-h co-culture of untreated
HCT116WT cells with untreated (red) CMTMR-labeled HCT116WT cells (aI–aIII, bI–bIII) and after 24-h co-culture of untreated HCT116WT cells with (red)
CMTMR-labeled HCT116WT cells that have been irradiated with 4 Gy of γ-ionizing radiation in the presence or absence of 100 μM Z-VAD-fmk (ZVAD)
or 100 μM Y-VAD-cmk (YVAD) (aIV–aVI, bIV–bVI) are shown. Frequencies of cells showing cytochrome c release (c), cleaved CASP3 (d), and nuclear
degradation (e) are shown (means ± SEM, n = 3). For c–e, asterisk (*) is used for “HCT116WT+OXA-treated HCT116WT”, “HCT116WT+CDDP-treated
HCT116WT”, “HCT116WT+PCT-treated HCT116WT”, and “HCT116WT+Irradiated (IR) HCT116WT” with “HCT116WT+control (Co.) HCT116WT” for nuclear
degradation and hash (#) is used for the comparison of inhibitor-treated cells with respective control cells for cytochrome c release, cleaved caspase3, or nuclear degradation. *, #p < 0.05; **, ##p < 0.01; ***, ###p < 0.001; and ####p < 0.0001
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Fig. 8 CAD and NCAD modalities elicited by chemotherapies and radiotherapy are distinctly regulated by p53 transcriptional activity.
Quantitative imaging ﬂow-cytometric detection of CAD and NCAD modalities was performed after 24 h (a, c, e, g) and 48 h (b, d, f, h) co-cultures of
untreated (red) CMTMR-labeled HCT116 p53R248W/+ cells with untreated (green) CMFDA-labeled HCT116 p53R248W/+ cells, or with OXA-, CDDP-, PCT- or
IR-treated (green) CMFDA-labeled HCT116 p53R248W/+ cells. Concentrations of OXA, CDDP, or PCT or doses of γ-irradiation used are indicated. The
frequencies of AV+D7− cells, AV−D7+ cells, and AV+D7+ cells were determined as previously described on total cell population (as revealed by
CMTMR+ or CMFDA+ HCT116 p53R248W/+ cells (a, b)), on untreated (red) CMTMR+ HCT116 p53R248W/+ cells (c, d), on untreated (green) CMFDA+
HCT116 cells (e, f), and on treated (green) CMFDA+ HCT116 p53R248W/+ (e, f). Means ± SEM are indicated (n = 3). For a–f, asterisk (*) is used for the
comparison of “HCT116 p53R248W/++OXA- or CDDP- or PCT- or IR-treated HCT116 p53R248W/+” with “HCT116+/++OXA- or CDDP- or PCT- or IR-treated
HCT116+/+” (from Figs. 2c–e, 3a–f, and 4a-c) for AV+D7−, and ampersand (&) is used for the comparison of “HCT116R248W/++OXA- or CDDP- or PCTor IR-treated HCT116 p53R248W/+” with “HCT116+/++OXA- or CDDP- or PCT- or IR-treated HCT116+/+” (from Figs. 2c–e, 3a–f, and 4a–c) for D7+. For
Fig. 7g, h, asterisk (*) is used for the comparison of “HCT116 p53R248W/++OXA- or CDDP- or PCT- or IR-treated HCT116 p53R248W/+” with “HCT116+/++OXAor CDDP- or PCT- or IR-treated HCT116+/+” (from Fig. 5b, c) for G(R), and ampersand (&) is used for comparison of “HCT116 p53R248W/++OXA- or
CDDP- or PCT- or IR-treated HCT116 p53R248W/+” with “HCT116+/++OXA- or CDDP- or PCT- or IR-treated HCT116+/+” (from Fig. 5b, c) for R(G). *, &p <
0.05; **, &&p < 0.01; ***p < 0.001; and ****, &&&&p < 0.0001

ﬂuorescence, CMFDA+). The following cell mixtures (at a
1/1 ratio) were performed: untreated CMTMR+ cancer
cells were mixed with untreated CMFDA+ cancer cells or
Ofﬁcial journal of the Cell Death Differentiation Association

untreated CMTMR+ cancer cells were mixed with treated
CMFDA+ cancer cells. Then cells were co-cultured during the indicated times in the presence or absence of the
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pharmacological inhibitor of ROCK, Y27632 (30 μM), the
pan-caspase inhibitor, Z-VAD-fmk (ZVAD, 100 μM), the
inhibitor of caspase-1, Ac-YVAD-cmk (YVAD, 100 μM),
the necroptosis inhibitor, NEC1 (30 μM), the inhibitor of
the vacuolar type H(+)-ATPase (V-ATPase) inhibiting
autophagy, BafA1 (50 nM), and the inhibitor of Cdks with
an anti-mitotic activity, Rosco (10 μM).
Cell death proﬁling by quantitative ﬂow imaging

After the indicated times of co-cultures, both detached
and adherent cells were collected and stained with
Hoechst 33342 (10 μg/mL) during 1 h at 37 °C in warmed
complete medium. To detect PS exposure and plasma
membrane permeability, labeled HCT116 cells were successively incubated with Biotin-AnnexinV (BD Pharmingen) as recommended by the manufacturer, 0.5 μg BV786Streptavidin (BD Biosciences), and 3 μM DRAQ7 (BioStatus) during 15 min at 25 °C. After washing with
phosphate-buffered saline (PBS) solution, samples were
immediately analyzed using an imaging ﬂow cytometer
FlowSight® (Amnis®, part of EMD Millipore). Data were
acquired at a 20× magniﬁcation, using the INSPIRE
software. The 405, 488, and 561 nm lasers were used for
excitation. Brightﬁeld, Annexin V-BV786, DRAQ7,
CMFDA, CMTMR, and Hoechst 33342 stainings were
detected using, respectively, channels for 420–480,
745–800, 642–745, 480–560, 595–642, and 430–505 nm.
At least 1000 events of cells per sample were analyzed.
Additional single-labeled controls were prepared to normalize ﬂuorescent signal across different channels.
Acquired data were analyzed using the IDEAS analysis
software (v6.1; Merck-Millipore). Gating strategy was the
following. Cells were gated for focused cells using the
Gradient RMS feature. Cells were gated for single cells
using the aspect ratio and area features. For the cannibalism detection, cells were gated in the double positive
CMFDA+ and CMTMR+ staining. The imaging ﬂow
cytometer FlowSight® provides the images of each events
and thus allows to remove from the analysis the artifacts
(such as cellular fragments or debris). We determined the
sample size required for analyzing the main types of cell
death elicited by anticancer treatments (such as apoptosis,
necrosis, and cellular cannibal) by calculating the statistical power of our method (statistical power = 0,8; α =
0,05; sampling ratio = 1). We found that the number of
cellular events that we need to acquire for obtaining statistically signiﬁcant results is ranging between 300 and
900 cellular events. Accordingly, 1000 cellular events per
condition were analyzed in Figs. 2a, b, o–q, 3m–o, 4j–l,
5d, e, and 6f, g, l, m and Supplementary Figures 1e, 2o-2q,
3m-3o, 4j-4l, and 5a-5d. To conﬁrm these results, we then
analyzed 10,000 cellular events per condition and validated previous results obtained with imaging ﬂow cytometer as shown in Figs. 2c–n,3a–l, 4a–i, 5b, c, k, l, 6b–e,
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h–k, and 8a–h. These results were also conﬁrmed using
conventional methods such as classical ﬂow cytometry
and microscopy (as shown in Fig. 3d–i).
Flow cytometry and confocal ﬂuorescent microscopy

To detect PS exposure, plasma membrane permeability,
and cell cycle progression, cells were after co-culture
sequentially labeled with speciﬁc ﬂuorescent probes (such
as ﬂuorescein isothiocyanate (FITC)-conjugated AnnexinV, propidium iodide (PI), and Hoechst 33342) and
analyzed by ﬂow cytometry. Both detached and adherent
cells were collected and stained with Hoechst 33345 (10
ug/ml) during 1 h at 37 °C in warmed complete medium.
After washing with PBS, HCT116 cells were suspended in
1× binding buffer supplemented with FITC-conjugated
Annexin V (BD Biosciences) and PI (1 μg/mL) (Sigma), as
per the manufacturer’s instructions. Samples were then
analyzed using LSRII ﬂow cytometer (Becton Dickinson)
and the FlowJo software v10. For confocal ﬂuorescence
microscopy, CMFDA- and CMTMR-labeled HCT116
cells
were
ﬁxed
after
co-culture
in
3.7%
paraformaldehyde–PBS for 15 min. Cells were either
counterstained with Hoechst 33342 (Invitrogen) and
analyzed for the detection of cell-in-cell structures or
permeabilized in 0.1% sodium dodecyl sulfate in PBS and
incubated with FBS for 20 min, as previously described39.
Primary antibodies for detection of cytochrome c (#6H2.
B4, Thermo Fisher Scientiﬁc) or cleaved caspase-3
(Asp175) (#9661, Cell Signaling Technology) were used
in PBS containing 1 mg/ml bovine serum albumin and
revealed with goat anti-rabbit immunoglobulin G (IgG)
conjugated to Alexa 488 ﬂuorochromes or with rabbit
anti-mouse IgG conjugated to Alexa 488 ﬂuorochromes
from Invitrogen. Then cells were counterstained with
Hoechst 33342 (Invitrogen) and analyzed by confocal SPE
microscope equipped with Apochromat 63× 1.3 NA and
63× 1.15 NA oil immersion objectives. The Leica Application Suite version 2.6 software was used (Leica
Microsystems).
Western blots

Total cellular proteins were extracted in lysis buffer
(containing 1% NP40, 20 mmol/L HEPES, 10 mmol/L
KCl, 1 mmol/L EDTA, 10% glycerol, protease, and phosphatase inhibitor tablets). Protein extracts (30 µg) were
run on 4–12% NuPAGE® Novex® Bis-Tris gels (Life
Technologies) and transferred at 4 °C onto Immobilon
polyvinyldiﬂuoride membranes (Thermo Scientiﬁc). After
blocking, membranes were incubated at 4 °C overnight
with primary antibodies speciﬁc for: caspase-3 (#9662),
cleaved caspase-3 (Asp175) (#9661), Myosin Light Chain
2 (MLC2) (#3672), phospho-MLC2 (Ser19) (#3675), LC3
A/B (#4108), and p-(S)-CDKs Substrate (#9477), obtained
from Cell Signaling Technology. Antibodies against
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GAPDH (#MAB374) were purchased from Millipore.
Horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit (Southern Biotechnology) antibodies were
then incubated for 1 h and revealed with the SuperSignal
West Pico® reagent (Thermo Fisher Scientiﬁc) or the
ECLTM Prime Western Blotting Detection System (GE
Healthcare) using an ImageQuant LAS 4000 softwareassisted imager (GE Healthcare).
Statistical analyses

Each experiment has been repeated at least three times,
yielding comparable results. Means and standard errors
(SEM) of three independent biological replicates are
shown. Data were analyzed by means of Prism v. 5.03
(GraphPad Software, La Jolla, CA, USA). Statistical signiﬁcance was assessed by one-way analysis of variance
tests. In all experiments, p values <0.05 were considered
as statistically signiﬁcant.
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